<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02739620</url>
  </required_header>
  <id_info>
    <org_study_id>M16-333</org_study_id>
    <nct_id>NCT02739620</nct_id>
  </id_info>
  <brief_title>Alternative Exercise Program to Improve Skeletal Muscle Function and Fatigue in Cancer Survivors</brief_title>
  <official_title>Alternative Exercise Program to Improve Skeletal Muscle Function and Fatigue in Cancer Survivors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Vermont</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Vermont</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exercise training has beneficial effects in cancer survivors to minimize some of the side
      effects of cancer and its treatment and improve long-term prognosis, but there are numerous
      hurdles for individuals diagnosed with, and being treated for, cancer to participate in
      exercise programs. The goal of this research study is to begin to evaluate whether exercise
      training via neuromuscular electrical stimulation (NMES) has beneficial effects on skeletal
      muscle size and function in cancer survivors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal calcium-activated tension single muscle fiber tension</measure>
    <time_frame>Change from baseline tension at 2 months</time_frame>
    <description>Tension (force per unit muscle fiber cross-sectional area) from segments of chemically-skinned single human muscle fibers will be assessed under maximal calcium-activated condition, with muscle fiber type determined post-measurement by gel electrophoresis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cross-sectional area of skeletal muscle fibers</measure>
    <time_frame>Change from baseline cross-sectional area at 2 months</time_frame>
    <description>Cross-sectional area of skeletal muscle fibers will be evaluated using immunohistochemistry, with specification of all relevant muscle fiber types</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intermyofibrillar mitochondrial content</measure>
    <time_frame>Change from baseline mitochondrial content at 2 months</time_frame>
    <description>Area fraction of intermyofibrillar mitochondria will be assessed by electron microscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mitochondrial function</measure>
    <time_frame>Change from baseline mitochondrial function at 2 months</time_frame>
    <description>Oxygen consumption rate of isolated muscle mitochondria under adenosine diphosphate stimulation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single muscle fiber contractile velocity</measure>
    <time_frame>Change from baseline contractile velocity at 2 months</time_frame>
    <description>Single muscle fiber contractile velocity assessed using isotonic load clamps, with muscle fiber type determined post-measurement by gel electrophoresis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>NMES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neuromuscular electrical stimulation (NMES) group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Neuromuscular electrical stimulation</intervention_name>
    <description>Neuromuscular electrical stimulation will be performed 5 times/week for one hour each day for 2 months.</description>
    <arm_group_label>NMES</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. stage I, II or III breast cancer

          2. receiving neoadjuvant or adjuvant chemotherapy with or without radiation

          3. a body mass index &lt;35 kg/m2.

        Exclusion Criteria:

          1. metastatic disease, a prior history of cancer, excluding non-melanoma skin cancer, or
             prior receipt of chemotherapy

          2. autoimmune, vascular or neuromuscular disease that could alter skeletal muscle

          3. prior knee or hip replacement

          4. contraindications for use of neuromuscular electrical stimulation, including an
             implanted cardiac defibrillator or pacemaker, lower extremity blood clot or
             coagulopathy

          5. pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J Toth, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Vermont</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Britta MacAlpine</last_name>
    <phone>802-735-6509</phone>
    <email>Britta.MacAlpine@uvmhealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Vermont College of Medicine</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Britta MacAlpine</last_name>
      <phone>802-735-6509</phone>
      <email>britta.macalpine@uvmhealth.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2016</study_first_submitted>
  <study_first_submitted_qc>April 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2016</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Vermont</investigator_affiliation>
    <investigator_full_name>Michael J. Toth, Ph.D.</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Research data (deidentified) which documents, supports and validates research findings will be stored on the University of Vermont College of Medicine computer system and will be made available upon final acceptance for publication of the major findings from the proposed studies. This includes raw data generated from all clinical and laboratory-based assessments under a data-sharing agreement.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

